References
- 1. Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs. 1994; 47(Suppl):3-7.
- 2. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004; 43:879-923.10.2165/00003088-200443130-00004
- 3. Micromedex Healthcare Series: Document 2007. Tramadol. Available from: http://www.thomsonhc.com/hcs/librarian/ND_PR/Main/SBK/3/PFPUI/7z16hW4.
- 4. Petrone D, Kamin M, Olson W. Slowing the titration rate of tramadol HCl reduces the incidence of discontinuation due to nausea and/ or vomiting: a double-blind randomized trial. J Clin Pharm Ther. 1999; 24:115-23.10.1046/j.1365-2710.1999.00203.x
- 5. Mercadante S, Arcuri E, Fusco F, Tirelli W, Villari P, Bussolino C, Campa T, De Conno F, Ripamonti C. Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-na_ve cancer patients with pain. Support Care Cancer. 2005; 13:702-7.10.1007/s00520-004-0760-9
- 6. Allen LV Jr. Compounding suppositories. Part I: theoretical considerations. Int J Pharm Compound. 2000; 4:289-93.
- 7. MIMS Thailand Index of Medical Specialties, 115th Edition, 2009.
- 8. British Pharmacopoeia 2007. CD version 11.0.
- 9. Yong CS, Oh YK, Jung SH, Rhee JD, Kim HD, Kim CK, Choi JS, Choi HG. Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol. Eur J Pharm Sci. 2004; 23:347-53.10.1016/j.ejps.2004.08.008
- 10. Woolfe G, MacDonald AD. The evaluation of the analgesic action of pethidine hydrochloride (Demerol). J Pharmacol Exp Ther. 1944; 80:300-7.
- 11. Yun MO, Choi HG, Jung JH, Kim CH. Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement. Int J Pharm. 1999; 189: 137-45.
- 12. Allen, LV Jr. Featured excipient: The poloxamers. Int J Pharm Compound. 2002; 6:58-9.
- 13. Miller SC, Drabik BR Rheological properties of poloxamer vehicles. Int J Pharm. 1984; 18:269-79.10.1016/0378-5173(84)90142-X
- 14. Choi HG, Lee MK, Kim MH, Kim CK. Effects of additives on the physicochemicasl properties of liquid suppository bases. Int J Pharm.1999; 190:13-9.
- 15. Barakat NS. In vitro and in vivo charecteristics of thermogelling rectal drug delivery. AAPS PharmSciTech. 2004; 10:724-31.10.1208/s12249-009-9261-y
- 16. Choi HG, Oh YK, Kim CK. In-situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int J Pharm. 1998; 165:23-32.
- 17. Hewitt WD. Compounded suppositories and pharmaceutical care. Int J Pharm Compound. 1997; 1: 93-9.
- 18. Hosny EA, Abdeel-Hady SS, El-Tahir K. Formulation, in vitro release and ex vivo spasmolytic effects of mebeverine hydrochloride suppositories containing polycarbophil or polysorbate 80. Int J Pharm. 1996; 142:163-8.
- 19. LeBars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev. 2001; 53:597- 652.
- 20. Sacerdote P, Bianchi M, Manfredi B, Panerai AE. Effects of tramadol on immune response and nociceptive thresholds in mice. Pain.1997; 72:325-30.